242 related articles for article (PubMed ID: 17579223)
1. Adjuvant chemotherapy with gemcitabine for patients with resectable pancreatic cancer.
Maisonneuve P; Lowenfels AB
JAMA; 2007 Jun; 297(23):2581; author reply 2582. PubMed ID: 17579223
[No Abstract] [Full Text] [Related]
2. Will gemcitabine monotherapy be dethroned as the adjuvant chemotherapy in pancreatic adenocarcinoma?
Kourie HR; Gharios J; Kattan J
Future Oncol; 2017 Feb; 13(3):197-199. PubMed ID: 27624286
[No Abstract] [Full Text] [Related]
3. Gemcitabine-induced hepatitis in a pancreatic cancer patient receiving adjuvant therapy following metastasectomy.
Saadati H; Peccerillo J; Kaley K; Schilsky ML; Saif MW
JOP; 2009 Sep; 10(5):573-5. PubMed ID: 19734642
[No Abstract] [Full Text] [Related]
4. Pancreatic cancer.
Clin Evid; 2003 Jun; (9):528-33. PubMed ID: 12967377
[No Abstract] [Full Text] [Related]
5. Adjuvant therapy for surgically resected pancreatic adenocarcinoma.
Abbruzzese JL
JAMA; 2008 Mar; 299(9):1066-7. PubMed ID: 18319419
[No Abstract] [Full Text] [Related]
6. [Chemoradiation for pancreatic adenocarcinoma].
Flandin I; Mornex F; Claude L; Kubas A; Khodri M; Wautot V; Mazeron R; Partensky C
Cancer Radiother; 2004 Nov; 8 Suppl 1():S80-7. PubMed ID: 15679252
[TBL] [Abstract][Full Text] [Related]
7. Management of a patient with borderline resectable pancreatic cancer. Case report and review.
Shah AP; Strauss JB; Leslie WT; Shah A; Mahon B; Abrams RA
Oncology (Williston Park); 2008 Nov; 22(13):1524-9. PubMed ID: 19133606
[TBL] [Abstract][Full Text] [Related]
8. Adjuvant chemotherapy with gemcitabine for patients with resectable pancreatic cancer.
Shivnani AT
JAMA; 2007 Jun; 297(23):2581-2; author reply 2582. PubMed ID: 17579222
[No Abstract] [Full Text] [Related]
9. Combined analysis of intratumoral human equilibrative nucleoside transporter 1 (hENT1) and ribonucleotide reductase regulatory subunit M1 (RRM1) expression is a powerful predictor of survival in patients with pancreatic carcinoma treated with adjuvant gemcitabine-based chemotherapy after operative resection.
Nakagawa N; Murakami Y; Uemura K; Sudo T; Hashimoto Y; Kondo N; Sueda T
Surgery; 2013 Apr; 153(4):565-75. PubMed ID: 23253379
[TBL] [Abstract][Full Text] [Related]
10. Phase I study of twice-weekly gemcitabine and concomitant external-beam radiotherapy in patients with adenocarcinoma of the pancreas.
Pipas JM; Mitchell SE; Barth RJ; Vera-Gimon R; Rathmann J; Meyer LP; Wagman RS; Lewis LD; McDonnell C; Colacchio TA; Perez RP
Int J Radiat Oncol Biol Phys; 2001 Aug; 50(5):1317-22. PubMed ID: 11483344
[TBL] [Abstract][Full Text] [Related]
11. Long-term effects of multimodal treatment for patients with resectable carcinoma of the pancreas.
Okabayashi T; Nishimori I; Nishioka A; Yamashita K; Sugimoto T; Dabanaka K; Maeda H; Kohsaki T; Ogawa Y; Kobayashi M; Onishi S; Hanazaki K
Oncol Rep; 2008 Sep; 20(3):651-6. PubMed ID: 18695919
[TBL] [Abstract][Full Text] [Related]
12. Successful adjuvant bi-weekly gemcitabine chemotherapy for pancreatic cancer without impairing patients' quality of life.
Toyama Y; Yoshida S; Saito R; Kitamura H; Okui N; Miyake R; Ito R; Son K; Usuba T; Nojiri T; Yanaga K
World J Surg Oncol; 2013 Jan; 11():3. PubMed ID: 23302293
[TBL] [Abstract][Full Text] [Related]
13. Adjuvant intra-arterial 5-fluoruracil, leucovorin, epirubicin and carboplatin with or without systemic gemcitabine after curative resection for pancreatic adenocarcinoma.
Cantore M; Serio G; Pederzoli P; Mambrini A; Iacono C; Pulica C; Capelli P; Lombardi M; Torri T; Pacetti P; Pagani M; Fiorentini G
Cancer Chemother Pharmacol; 2006 Oct; 58(4):504-8. PubMed ID: 16633830
[TBL] [Abstract][Full Text] [Related]
14. Predictive and prognostic roles of ribonucleotide reductase M1 in resectable pancreatic adenocarcinoma.
Xie H; Jiang W; Jiang J; Wang Y; Kim R; Liu X; Liu X
Cancer; 2013 Jan; 119(1):173-81. PubMed ID: 22736490
[TBL] [Abstract][Full Text] [Related]
15. Clinical update of gemcitabine in pancreas cancer.
Au E
Gan To Kagaku Ryoho; 2000 May; 27 Suppl 2():469-73. PubMed ID: 10895197
[TBL] [Abstract][Full Text] [Related]
16. The clinical efficacy of adjuvant systemic chemotherapy with gemcitabine in node-positive pancreatic cancer.
Kurosaki I; Hatakeyama K
Hepatogastroenterology; 2004; 51(57):634-7. PubMed ID: 15143880
[TBL] [Abstract][Full Text] [Related]
17. [Chemotherapy, chemoradiotherapy or observation after complete resection of pancreatic adenocarcinoma?].
Lluís F
Gastroenterol Hepatol; 2009 Feb; 32(2):120-1. PubMed ID: 19231687
[No Abstract] [Full Text] [Related]
18. Postoperative adjuvant gemcitabine and concurrent radiation after curative resection of pancreatic head carcinoma: a phase II study.
Van Laethem JL; Demols A; Gay F; Closon MT; Collette M; Polus M; Houbiers G; Gastelblum P; Gelin M; Houtte PV; Closset J
Int J Radiat Oncol Biol Phys; 2003 Jul; 56(4):974-80. PubMed ID: 12829132
[TBL] [Abstract][Full Text] [Related]
19. Second-line therapy in gemcitabine-pretreated patients with advanced pancreatic cancer.
Boeck S; Heinemann V
J Clin Oncol; 2008 Mar; 26(7):1178-9; author reply 1179. PubMed ID: 18309957
[No Abstract] [Full Text] [Related]
20. High expression of survivin is prognostic of shorter survival but not predictive of adjuvant gemcitabine benefit in patients with resected pancreatic adenocarcinoma.
Xie H; Jiang W; Xiao SY; Liu X
J Histochem Cytochem; 2013 Feb; 61(2):148-55. PubMed ID: 23124118
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
